Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response
GastroHep · 2021-03 · 3 (2) · 63-71
DOI: 10.1002/ygh2.444 ↗Kurz gefasst
Fachartikel in der Zeitschrift GastroHep, online erschienen am 28.02.2021. Verfasst von An Outtier und 14 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Outtier, A., Wauters, L., Rahier, J., Bossuyt, P., Colard, A., Franchimont, D., Lambrecht, G., Macken, E., Moerkercke, W. V., Baert, F., Humblet, E., Hootegem, P. V., Gils, A., Ferrante, M., & Vermeire, S. (2021). Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. GastroHep, 3(2), 63-71. https://doi.org/10.1002/ygh2.444
Vancouver
Outtier A, Wauters L, Rahier J, Bossuyt P, Colard A, Franchimont D, et al. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. GastroHep. 2021;3(2):63-71. doi:10.1002/ygh2.444
BibTeX
@article{Outtier2021,
author = {Outtier, An and Wauters, Lucas and Rahier, Jean‐Francois and Bossuyt, Peter and Colard, Arnaud and Franchimont, Denis and Lambrecht, Guy and Macken, Elisabeth and Moerkercke, Wouter Van and Baert, Filip and Humblet, Evelien and Hootegem, Philippe Van and Gils, Ann and Ferrante, Marc and Vermeire, Séverine},
title = {Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response},
journal = {GastroHep},
year = {2021},
volume = {3},
number = {2},
pages = {63--71},
doi = {10.1002/ygh2.444}
}
EUVIMED